Systemic and Mucosal Differences in HIV Burden, Immune, and Therapeutic Responses

Background:Mucosal tissues represent major targets for HIV transmission but differ in susceptibility and reservoir function by unknown mechanisms. Methods:In a cross-sectional study, HIV RNA and infectious virus were compared between oral and genital compartments and blood in HIV-infected women, in association with clinical parameters, copathogens, and putative innate and adaptive HIV inhibitors. Results:HIV RNA was detectable in 24.5% of women from all 3 compartments, whereas 45% had RNA in only 1 or 2 sites. By comparison, infectious HIV, present in blood of the majority, was rare in mucosal sites. Innate mediators, secretory leukocyte protease inhibitor and thrombospondin, were highest in mucosae. Highly active antiretroviral therapy was associated with an 80% decreased probability of shedding. Multivariate logistic regression models revealed that mucosal HIV RNA was associated with higher plasma RNA, infectious virus, and total mucosal IgA, but not IgG. There was a 37-fold increased probability of detecting RNA in both genital and oral specimens (P = 0.008; P = 0.02, respectively) among women in highest versus lowest IgA tertiles. Conclusions:Mucosal sites exhibit distinct characteristics of infectious HIV, viral shedding, and responses to therapy, dependent upon both systemic and local factors. Of the putative innate and adaptive mucosal defense factors examined, only IgA was associated with HIV RNA shedding. However, rather than being protective, there was a striking increase in probability of detectable HIV RNA shedding in women with highest total IgA.

[1]  S. Wahl,et al.  The mouth: a gateway or a trap for HIV? , 2010, AIDS.

[2]  A. Wright,et al.  Excretion of Human Immunodeficiency Virus Type 1 through Polarized Epithelium by Immunoglobulin A , 2008, Journal of Virology.

[3]  Charles Poole,et al.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[4]  Sarah S. Wilson,et al.  Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism , 2008, Journal of Virology.

[5]  Susan Moir,et al.  Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. , 2008, The Journal of allergy and clinical immunology.

[6]  D. Boutolleau,et al.  Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum , 2008, Journal of Clinical Microbiology.

[7]  John P. Moore,et al.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.

[8]  R. Kaul,et al.  HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers , 2008, AIDS.

[9]  M. Kazatchkine,et al.  Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. , 2008, Virology.

[10]  A. Ding,et al.  Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI , 2007, Nature Immunology.

[11]  M. Clerici,et al.  Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. , 2006, The Journal of pediatrics.

[12]  S. Wahl,et al.  HIV accomplices and adversaries in macrophage infection , 2006, Journal of leukocyte biology.

[13]  D. Shugars,et al.  Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity , 2005, Journal of Virology.

[14]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[15]  J. Mestecky,et al.  Immunologic Uniqueness of the Genital Tract: Challenge for Vaccine Development , 2005, American journal of reproductive immunology.

[16]  S. Wahl,et al.  Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection , 2004, The Journal of experimental medicine.

[17]  R. Rogers,et al.  Oral manifestations of sexually transmitted diseases. , 2004, Clinics in dermatology.

[18]  M. Mulligan,et al.  Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. , 2004, AIDS research and human retroviruses.

[19]  J. Sallenave,et al.  Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. , 2004, Current pharmaceutical design.

[20]  A. Wald,et al.  Genital herpes and human immunodeficiency virus: double trouble. , 2004, Bulletin of the World Health Organization.

[21]  G. Slade,et al.  Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.

[22]  Don Smith HIV and herpes co-infection, an unfortunate partnership. , 2004, Journal of HIV therapy.

[23]  J. Dilley,et al.  Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. , 2002, AIDS.

[24]  B. Richardson,et al.  Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. , 2002, The Journal of infectious diseases.

[25]  L. Lopalco,et al.  Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. , 2002, Journal of acquired immune deficiency syndromes.

[26]  Mardge H. Cohen,et al.  Determinants of HIV-1 shedding in the genital tract of women , 2001, The Lancet.

[27]  J. Bremer,et al.  Longitudinal Variability of Human Immunodeficiency Virus Type 1 RNA Viral Load Measurements by Nucleic Acid Sequence-Based Amplification and NucliSens Assays in a Large Multicenter Study , 2001, Journal of Clinical Microbiology.

[28]  L. Lopalco,et al.  Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. , 2001, AIDS.

[29]  L. Kuhn,et al.  Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. , 2001, The Journal of infectious diseases.

[30]  P. Cristoforoni,et al.  Effects of Human Papillomavirus‐Associated Cells on Human Immunodeficiency Virus Gene Expression , 2000, Obstetrics and gynecology.

[31]  F. Lucht,et al.  Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. , 2000, The Journal of infectious diseases.

[32]  O. Bagasra,et al.  Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 8 DNA in Semen , 1999, Journal of Clinical Microbiology.

[33]  S. Huong,et al.  Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation. , 1999, Journal of human virology.

[34]  J. Orenstein,et al.  The macrophage origin of the HIV-expressing multinucleated giant cells in hyperplastic tonsils and adenoids. , 1999, Ultrastructural pathology.

[35]  L. Kalish,et al.  Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. , 1999, Journal of the National Cancer Institute.

[36]  D. Isenberg,et al.  Structural basis of the gp120 superantigen-binding site on human immunoglobulins. , 1998, Journal of immunology.

[37]  M. Schluchter,et al.  Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study : The role of EBV shedding , 1998 .

[38]  L. Mortimer,et al.  Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. , 1998, The Journal of infectious diseases.

[39]  M. Gisslén,et al.  Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. , 1998, AIDS research and human retroviruses.

[40]  D. Ho,et al.  HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy , 1998, The Journal of experimental medicine.

[41]  S. Wahl,et al.  The role of the oral environment in HIV-1 transmission. , 1998, Journal of the American Dental Association.

[42]  T. Schacker,et al.  Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. , 1998, JAMA.

[43]  D. Anderson,et al.  Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. , 1998, AIDS research and human retroviruses.

[44]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[45]  R. Silverstein,et al.  Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.

[46]  S. Wahl,et al.  Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. , 1997, Blood.

[47]  Phillip D. Smith,et al.  IMMUNOBIOLOGY OF MUCOSAL HIV-1 INFECTION , 1996 .

[48]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[49]  P. D. Smith,et al.  Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. , 1995, The Journal of infectious diseases.

[50]  T. Lehner,et al.  Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. , 1995, Immunology.

[51]  D. Dripps,et al.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.

[52]  R. Crystal,et al.  Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. , 1991, The Journal of clinical investigation.

[53]  Noel R. Rose,et al.  Manual of clinical laboratory immunology , 2002 .

[54]  L. Kalish,et al.  The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.

[55]  M. Schluchter,et al.  Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[56]  K. Holmes,et al.  Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations , 1983 .

[57]  D. Pittet,et al.  COOK County Hospital. , 1956, Medical times.